Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'GLYCOPROTEIN-IIB-IIIA' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 1280 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Casterella, PJ; Kereiakes, DJ; Steinhubl, SR; Raymond, RE; Kottke-Marchant, K; Patel, K; Mueller, M; Rosenthal, M; Moliterno, DJ; Teirstein, PS
      The platelet function dose-response to abciximab during percutaneous coronary revascularization is variable

      CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
    2. Lincoff, AM
      Anticoagulant and antiplatelet drugs

      CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
    3. McCollam, PL; Lage, MJ; Bala, M
      A comparison of total hospital costs for percutaneous coronary intervention patients receiving abciximab versus tirofiban

      CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
    4. Paradiso-Hardy, FL; Madan, M; Radhakrishnan, S; Hurden, S; Cohen, EA
      Severe thrombocytopenia possibly related to readministration of eptifibatide

      CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
    5. Simon, DI; Liu, CB; Ganz, P; Kirshenbaum, JM; Piana, RN; Rogers, C; Selwyn, AP; Popma, JJ
      A comparative study of light transmission aggregometry and automated bedside platelet function assays in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibatide, or tirofiban

      CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
    6. Martin, GS
      The hunting of the Src

      NATURE REVIEWS MOLECULAR CELL BIOLOGY
    7. Kiefel, V
      Platelet antibodies and diagnosis of immune-mediated thrombocytopenia

      INFUSION THERAPY AND TRANSFUSION MEDICINE-INFUSIONSTHERAPIE UND TRANSFUSIONSMEDIZIN
    8. Inwald, D; Davies, EG; Klein, N
      Demystified ... Adhesion molecule deficiencies

      JOURNAL OF CLINICAL PATHOLOGY-MOLECULAR PATHOLOGY
    9. Akkerhuis, KM; van den Brand, MJBM; van der Zwaan, C; Peels, HOJ; Suryapranata, H; van der Wieken, LR; Stibbe, J; Hoffmann, J; Baardman, T; Deckers, JW; Simoons, ML
      Pharmacodynamics and safety of lefradafiban, an oral platelet glycoproteinIIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty

      HEART
    10. Vaisman, D; Ferguson, JJ
      Therapeutic potential of GP IIb/IIIa receptor antagonists in acute myocardial infarction

      EXPERT OPINION ON INVESTIGATIONAL DRUGS
    11. Nurden, P
      The anti-GPIIb-IIIa

      TRANSFUSION CLINIQUE ET BIOLOGIQUE
    12. Schmidt, AM; Stern, DM
      Chemokines on the rise - MCP-1 and restenosis

      ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
    13. Collett, JP; Montalescot, G; Lesty, C; Soria, J; Mishal, Z; Thoms, D; Soria, C
      Disaggregation of in vitro preformed platelet-rich clots by abciximab increases fibrin exposure and promotes fibrinolysis

      ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
    14. Abulencia, JP; Tien, N; McCarty, OJT; Plymire, D; Mousa, SA; Konstantopoulos, K
      Comparative antiplatelet efficacy of a novel, nonpeptide GPIIb/IIIa antagonist (XV454) and abciximab (c7E3) in flow models of thrombosis

      ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
    15. Casonato, A; Pontara, E; Vertolli, UP; Steffan, A; Durante, C; De Marco, L; Sartorello, F; Girolami, A
      Plasma and platelet von Willebrand factor abnormalities in patients with uremia: Lack of correlation with uremic bleeding

      CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
    16. Santillan, MKO; Herring, J; Hoppensteadt, DA; Jeske, W; Herbert, JM; Fareed, J
      The effect of a novel glycoprotein IIb/IIIa antagonist, SR 121566A, on platelet aggregation and activation in rhesus monkeys

      CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
    17. Axelrod, DA; Wakefield, TW
      Future directions in antithrombotic therapy: Emphasis on venous thromboembolism

      JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
    18. Spinler, SA; Hilleman, DE; Cheng, JWM; Howard, PA; Mauro, VF; Lopez, LM; Munger, MA; Gardner, SF; Nappi, JM
      New recommendations from the 1999 American College of Cardiology/American Heart Association acute myocardial infarction guidelines

      ANNALS OF PHARMACOTHERAPY
    19. Clutton, P; Folts, JD; Freedman, JE
      Pharmacological control of platelet function

      PHARMACOLOGICAL RESEARCH
    20. Bogousslavsky, J; Leclerc, JR
      Platelet glycoprotein IIb/IIIa blockade in acute ischemic stroke

      CEREBROVASCULAR DISEASES
    21. Easton, JD
      Future perspectives for optimizing oral antiplatelet therapy

      CEREBROVASCULAR DISEASES
    22. Knight, LC
      Radiolabeled peptide ligands for imaging thrombi and emboli

      NUCLEAR MEDICINE AND BIOLOGY
    23. Hantgan, RR; Rocco, M; Nagaswami, C; Weisel, JW
      Binding of a fibrinogen mimetic stabilizes integrin alpha IIb beta 3's open conformation

      PROTEIN SCIENCE
    24. Manaka, A; Sato, M; Aoki, M; Tanaka, M; Ikeda, T; Toda, Y; Yamane, Y; Nakaike, S
      2-acylimino-3H-thiazoline derivatives: A novel template for platelet GPIIb/IIIa receptor antagonists

      BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
    25. Ervin, AL; Peerschke, EIB
      Platelet activation by sustained exposure to low-dose plasmin

      BLOOD COAGULATION & FIBRINOLYSIS
    26. Phillips, DR; Prasad, KSS; Manganello, J; Bao, M; Nannizzi-Alaimo, L
      Integrin tyrosine phosphorylation in platelet signaling

      CURRENT OPINION IN CELL BIOLOGY
    27. Holmes, MB; Kabbani, SS; Terrien, CM; Watkins, MW; Sobel, BE; Schneider, DJ
      Quantification by flow cytometry of the efficacy of and interindividual variation of platelet inhibition induced by treatment with tirofiban and abciximab

      CORONARY ARTERY DISEASE
    28. Lucore, CL; Trask, RV; Mishkel, GJ; Rocha-Singh, KJ; Shelton, ME; Mikell, FL; Ligon, RW
      Impact of abciximab and coronary stenting on outcomes and costs of percutaneous coronary interventions in a community hospital

      CORONARY ARTERY DISEASE
    29. Kereiakes, DJ; Lorenz, T; Young, JJ; Kukielka, G; Mueller, MN; Nanniazzi-Alaimo, L; Phillips, DR
      Differential effects of citrate versus PPACK anticoagulation on measured platelet inhibition by abciximab, eptifibatide and tirofiban

      JOURNAL OF THROMBOSIS AND THROMBOLYSIS
    30. Januzzi, JL; Chae, CU; Sabatine, MS; Jang, IK
      Elevation in serum troponin I predicts the benefit of tirofiban

      JOURNAL OF THROMBOSIS AND THROMBOLYSIS
    31. Smith, BS; Gandhi, PJ
      Pharmacokinetics and pharmacodynamics of low-molecular-weight heparins andglycoprotein IIb/IIIa receptor antagonists in renal failure

      JOURNAL OF THROMBOSIS AND THROMBOLYSIS
    32. Mine, S; Fujisaki, T; Suematsu, M; Tanaka, Y
      Activated platelets and endothelial cell interaction with neutrophils under flow conditions

      INTERNAL MEDICINE
    33. Zhang, YH; Chung, KH; Ryu, CK; Lee, YH; Kim, TJ; Song, YS; Hwang, KA; Yun, YP
      Antiplatelet mechanism of 2-chloro-3-(4-hexylphenyl)amino-1,4-naphthoquinone (NQ304), an antithrombotic agent

      PHARMACOLOGY & TOXICOLOGY
    34. Nagahama, M; Nomura, S; Ozaki, Y; Yoshimura, C; Kagawa, H; Fukuhara, S
      Platelet activation markers and soluble adhesion molecules in patients with systemic lupus erythematosus

      AUTOIMMUNITY
    35. Missy, K; Giuriato, S; Bodin, S; Plantavid, M; Payrastre, B
      Integrins and signal transduction: illustration with the alpha(IIb)beta(3)integrin in platelets

      M S-MEDECINE SCIENCES
    36. Lin, PH; Bush, RL; Tong, FC; Chaikof, E; Martin, LG; Lumsden, AB
      Intra-arterial thrombin injection of an ascending aortic pseudoaneurysm complicated by transient ischemic attack and rescued with systemic abciximab

      JOURNAL OF VASCULAR SURGERY
    37. Anderson, KM; Califf, RM; Stone, GW; Neumann, FJ; Montalescot, G; Miller, DP; Ferguson, JJ; Willerson, JT; Weisman, HF; Topol, EJ
      Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention

      JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
    38. Neumann, FJ; Hochholzer, W; Pogatsa-Murray, G; Schomig, A; Gawaz, M
      Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting

      JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
    39. Lev, EI; Osende, JI; Richard, MF; Robbins, JA; Delfin, JA; Rodriguez, O; Sharma, SK; Jayasundera, T; Badimon, JJ; Marmur, JD
      Administration of abciximab to patients receiving tirofiban or eptifibatide: Effect on platelet function

      JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
    40. Salvati, F; Liani, M
      Role of platelet surface receptor abnormalities in the bleeding and thrombotic diathesis of uremic patients on hemodialysis and peritoneal dialysis

      INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS
    41. Rossi, F; Rossi, E; Pareti, FI; Colli, S; Tremoli, E; Gallo, L
      In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion

      HAEMATOLOGICA
    42. Keh, D; Kurer, I; Dudenhausen, JW; Woltmann, W; Falke, KJ; Gerlach, H
      Response of neonatal platelets to nitric oxide in vitro

      INTENSIVE CARE MEDICINE
    43. Goldmann, BU; Hamm, CW
      Risk stratification in acute coronary syndrome

      HERZ
    44. Schror, K
      Pathophysiology of platelet activation and pharmacology of GPIIb/IIIa antagonists

      HERZ
    45. Rendu, F; Brohard-Bohn, B; Pain, S; Bachelot-Loza, C; Auger, J
      Thiosulfinates inhibit platelet aggregation and microparticle shedding at a calpain-dependent step

      THROMBOSIS AND HAEMOSTASIS
    46. Topaz, O; Minisi, AJ; Bernardo, NL; McPherson, RA; Martin, E; Carr, SL; Carr, ME
      Alterations of platelet aggregation kinetics with ultraviolet laser emission: The "stunned platelet" phenomenon

      THROMBOSIS AND HAEMOSTASIS
    47. Derrick, JM; Shattil, SJ; Poncz, M; Gruppo, RA; Gartner, TK
      Distinct domains of alpha IIb beta 3 support different aspects of outside-in signal transduction and platelet activation induced by LSARLAF, an alphaIIb beta 3 interacting peptide

      THROMBOSIS AND HAEMOSTASIS
    48. Marques, JA; George, JK; Smith, IJ; Bhakta, V; Sheffield, WP
      A barbourin-albumin fusion protein that is slowly cleared in vivo retains the ability to inhibit platelet aggregation in vitro

      THROMBOSIS AND HAEMOSTASIS
    49. Fox, JEB
      Cytoskeletal proteins and platelet signaling

      THROMBOSIS AND HAEMOSTASIS
    50. Shattil, SJ; Leavitt, AD
      All in the family: Primary megakaryocytes for studies of platelet alpha IIb beta(3) signaling

      THROMBOSIS AND HAEMOSTASIS
    51. Woodside, DG; Liu, S; Ginsberg, MH
      Integrin activation

      THROMBOSIS AND HAEMOSTASIS
    52. Coller, BS
      Anti-GPIIb/IIIa drugs: Current strategies and future directions

      THROMBOSIS AND HAEMOSTASIS
    53. Sassoli, PM; Emmell, EL; Tam, SH; Trikha, M; Zhou, Z; Jordan, RE; Nakada, MT
      7E3 F(ab ')(2), an effective antagonist of rat alpha IIb beta 3 and alpha v beta 3, blocks in vivo thrombus formation and in vitro angiogenesis

      THROMBOSIS AND HAEMOSTASIS
    54. Bennett, JS; Mousa, S
      Platelet function inhibitors in the year 2000

      THROMBOSIS AND HAEMOSTASIS
    55. Israels, SJ; McMillan-Ward, EM; Easton, J; Robertson, C; McNicol, A
      CD63 associates with the alpha(IIb)beta(3) integrin-CD9 complex on the surface of activated platelets

      THROMBOSIS AND HAEMOSTASIS
    56. Klinkhardt, U; Graff, J; Westrup, D; Kirchmaier, CM; Esslinger, HU; Breddin, HK; Harder, S
      Pharmacodynamic characterization of the interaction between abciximab or tirofiban with unfractionated or a low molecular weight heparin in healthy subjects

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    57. Graff, J; Andries, D; Elsner, M; Westrup, D; Bassus, S; Franz, N; Klinkhardt, U; Harder, S
      Platelet CD62 expression and PDCFAB secretion in patients undergoing PTCA and treatment with abciximab

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    58. Dopheide, SM; Yap, CL; Jackson, SP
      Dynamic aspects of platelet adhesion under flow

      CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
    59. Boudreaux, MK; Lipscomb, DL
      Clinical, biochemical, and molecular aspects of Glanzmann's thrombastheniain humans and dogs

      VETERINARY PATHOLOGY
    60. Galeote, G; Pastor, AA; Carcamo, C; Sobrino, N; Calvo, L; Munoz, SG; Hussein, M; Fernandez-Chacon, JL; Sobrino, JA
      Variable response to the biological inhibition of platelets by abciximab in patients subjected to percutaneous coronary angioplasty

      REVISTA ESPANOLA DE CARDIOLOGIA
    61. Cokkinos, DV
      The treatment of coronary heart disease: An update - Part 4: Acute ischaemic coronary syndromes

      CURRENT MEDICAL RESEARCH AND OPINION
    62. Mathis, AS; Meswani, P; Spinler, SA
      Risk stratification in non-ST segment elevation acute coronary syndromes with special focus on recent guidelines

      PHARMACOTHERAPY
    63. Spinler, SA; Inverso, SM
      Update on strategies to improve thrombolysis for acute myocardial infarction

      PHARMACOTHERAPY
    64. McKay, RG; Boden, WE
      Small peptide GP IIb/IIIa receptor inhibitors as upstream therapy in non-ST-segment elevation acute coronary syndromes: results of the PURSUIT, PRISM, PRISM-PLUS, TACTICS, and PARAGON trials

      CURRENT OPINION IN CARDIOLOGY
    65. Chan, AW; Moliterno, DJ
      Defining the role of abciximab for acute coronary syndromes: lessons from CADILLAC, ADMIRAL, GUSTO IV, GUSTO v, and TARGET

      CURRENT OPINION IN CARDIOLOGY
    66. Chang, CP; Chang, JC; Chang, HH; Tsai, WJ; Lo, SCJ
      Positional importance of Pro(53) adjacent to the Arg(49)-Gly(50)-Asp(51) sequence of rhodostomin in binding to integrin alpha IIb beta 3

      BIOCHEMICAL JOURNAL
    67. Gimeno, MJ; Gonzalez, J; Rodriguez, M; Corrales, C; Bellon, JM; Bujan, J
      Potential role of a new anti-beta 3 integrin antibody in the development of intimal hyperplasia after vascular surgery: an in vitro smooth muscle cell model

      HISTOLOGY AND HISTOPATHOLOGY
    68. Nicholson, NS; Abood, NA; Panzer-Knodle, SG; Frederick, LG; Page, JD; Salyers, AK; Suleymanov, OD; Szalony, JA; Taite, BB; Anders, RJ
      Orbofiban: An orally active GPIIB/IIIa platelet receptor antagonist

      MEDICINAL RESEARCH REVIEWS
    69. Christov, A; Kostuk, WJ; Jablonsky, G; Lucas, A
      Fluorescence spectroscopic analysis of circulating platelet activation during coronary angioplasty

      LASERS IN SURGERY AND MEDICINE
    70. Tcheng, JE; Strony, J; Lorenz, TJ; O'Shea, JC
      ESPRIT in context: pharmacology matters!

      EUROPEAN HEART JOURNAL
    71. Loubeyre, C; Lefevre, T; Louvard, Y; Dumas, P; Piechaud, JF; Lanore, JJ; Angellier, JF; Le Tarnec, JY; Karrillon, G; Margenet, A; Pouges, C; Morice, MC
      Outcome after combined reperfusion therapy for acute myocardial infarction, combining pre-hospital thrombolysis with immediate percutaneous coronary intervention and stent

      EUROPEAN HEART JOURNAL
    72. Zwart-van Rijkom, JEF; Klungel, OH; Leufkens, HGM; Broekmans, AW; Schrijver-van Velthoven, S; Umans, VA
      Costs and effects of combining stenting and abciximab (ReoPro (R)) in daily practice

      INTERNATIONAL JOURNAL OF CARDIOLOGY
    73. Suvire, FD; Rodriguez, AM; Mak, ML; Papp, JG; Enriz, RD
      Binding mechanism of RGD and its mimetics to receptor GPIIb/IIIa. A theoretical study

      JOURNAL OF MOLECULAR STRUCTURE-THEOCHEM
    74. Fry, ETA
      Glycoprotein IIb/IIIa inhibitors and low-molecular-weight heparins: A combined role in coronary interventions?

      CLINICAL CARDIOLOGY
    75. Kang, WS; Chung, KH; Chung, JH; Lee, JY; Park, JB; Zhang, YH; Yoo, HS; Yun, YP
      Antiplatelet activity of green tea catechins is mediated by inhibition of cytoplasmic calcium increase

      JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
    76. Amoroso, G; van Boven, AJ; van Veldhuisen, DJ; Tio, RA; Balje-Volkers, CP; Petronio, AS; van Oeveren, W
      Eptifibatide and abciximab exhibit equivalent antiplatelet efficacy in an experimental model of stenting in both healthy volunteers and patients withcoronary artery disease

      JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
    77. Truong, KM; Amankwa, K; Kucukarslan, S
      Platelet glycoprotein IIb/IIIa-receptor inhibitors in patients with acute coronary syndromes or undergoing percutaneous coronary interventions: A review

      CLINICAL THERAPEUTICS
    78. Qureshi, AI; Ali, Z; Suri, MFK; Kim, SH; Fessler, RD; Ringer, AJ; Guterman, LR; Hopkins, LN
      Open-label phase I clinical study to assess the safety of intravenous eptifibatide in patients undergoing internal carotid artery angioplasty and stent placement

      NEUROSURGERY
    79. Akkerhuis, KM; Deckers, JW; Lincoff, AM; Tcheng, JE; Boersma, E; Anderson, K; Balog, C; Califf, RM; Topol, EJ; Simoons, ML
      Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention

      JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
    80. Pu, Q; Wiel, E; Corseaux, D; Bordet, R; Azrin, MA; Ezekowitz, MD; Lund, N; Jude, B; Vallet, B
      Beneficial effect of glycoprotein IIb/IIIa inhibitor (AZ-1) on endotheliumin Escherichia coli endotoxin-induced shock

      CRITICAL CARE MEDICINE
    81. Parker, RI
      IIb/IIIa or not IIb/IIIa, that is adhesion

      CRITICAL CARE MEDICINE
    82. Bennett, JS
      Novel platelet inhibitors

      ANNUAL REVIEW OF MEDICINE
    83. Park, JW; Smolen, J
      Monoclonal antibody therapy

      ADVANCES IN PROTEIN CHEMISTRY, VOL 56
    84. Wang, XF; Liu, FQ; Morris, SA; Carroll, RC
      Synergistic outside-in regulation of platelet activation by GPIIb/IIIa ligand-induced conformation and oligomerization

      THROMBOSIS RESEARCH
    85. Sakariassen, KS; Hanson, SR; Cadroy, Y
      Methods and models to evaluate shear-dependent and surface reactivity-dependent antithrombotic efficacy

      THROMBOSIS RESEARCH
    86. Damiano, BP; Mitchell, JA; Giardino, E; Corcoran, T; Haertlein, BJ; de Garavilla, L; Kauffman, JA; Hoekstra, WJ; Maryanoff, BE; Andrade-Gordon, P
      Antiplatelet and antithrombotic activity of RWJ-53308, a novel orally active glycoprotein IIb/IIIa antagonist

      THROMBOSIS RESEARCH
    87. Cook, BC
      Reactivity of human platelets with immobilized fibrinogen is dictated by the chemical character of the surface

      THROMBOSIS RESEARCH
    88. Mousa, SA; Forsythe, MS
      Comparison of the effect of different platelet GPIIb/IIa antagonists on the dynamics of platelet/fibrin-mediated clot strength induced using thromboelastography

      THROMBOSIS RESEARCH
    89. Erhardt, JA; Ohlstein, EH; Toomey, JR; Gabriel, MA; Willette, RN; Yue, TL; Barone, FC; Parsons, AA
      Activation of caspase-3/caspase-3-like activity in rat cardiomyocytes by an RGD peptide, but not the GPIIb/IIIa antagonist lotrafiban

      THROMBOSIS RESEARCH
    90. Peter, K; Schwarz, M; Nordt, T; Bode, C
      Intrinsic activating properties of GP IIb/IIIa blockers

      THROMBOSIS RESEARCH
    91. Rossi, ML; Merlini, PA; Ardissino, D
      Percutaneous coronary revascularisation in women

      THROMBOSIS RESEARCH
    92. Verheugt, FWA
      GP IIB/IIIA blockers with and without thrombolytic agent in prehospital treatment of acute myocardial infarction

      THROMBOSIS RESEARCH
    93. Darius, H
      Oral glycoprotein Ilb/IIa antagonists for unstable angina - Is there stilla chance for the oral substances?

      THROMBOSIS RESEARCH
    94. Haumer, M; Atteneder, M; Ahmadi, R; Schillinger, M; Minar, E
      Coadministration of low-dose urokinase and abciximab in thrombolysis for lower limb ischemia - A safety study

      THROMBOSIS RESEARCH
    95. Huang, TC; Jordan, RE; Hantgan, RR; Alevriadou, BR
      Differential effects of c7E3 Fab on thrombus formation and rt-PA-mediated thrombolysis under flow conditions

      THROMBOSIS RESEARCH
    96. Shenkman, B; Schneiderman, J; Tamarin, I; Kotev-Emeth, S; Savion, N; Varon, D
      Testing the effect of GPIIb-IIIa antagonist in patients undergoing carotidstenting: Correlation between standard aggregometry, flow cytometry and the cone and plate(let) analyzer (CPA) methods

      THROMBOSIS RESEARCH
    97. Alfon, J; de Arriba, AF; Gomez-Casajus, LA; Merlos, M
      Alternative binding assay of GP IIb/IIIa antagonists with a nonradioactivelabeling method of platelets

      THROMBOSIS RESEARCH
    98. Ahmad, S; Jeske, WP; Ma, Q; Walenga, JM; Fareed, J
      Inhibition of tissue factor-activated platelets by low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonist

      THROMBOSIS RESEARCH
    99. Harder, S; Klinkhardt, U; Graff, J; Westrup, D; Kirchmaier, CM; Glusa, E; Mascelli, MA; Marciniak, SJ; Just, A; Losche, W; Breddin, HK
      In vitro dose response to different GPIIb/IIIa-antagonists: Inter-laboratory comparison of various platelet function tests

      THROMBOSIS RESEARCH
    100. Kageyama, S; Yamamoto, H; Nakazawa, H; Yoshimoto, R
      Anti-human vWF monoclonal antibody, AJvW-2 fab, inhibits repetitive coronary artery thrombosis without bleeding time prolongation in dogs

      THROMBOSIS RESEARCH


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 08/08/20 alle ore 05:48:57